NCT04552288

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Phase II Study of IL-5-receptor-alpha-chain (IL-5Rα) Inhibition With Benralizumab for Eosinophil-Related Cutaneous Adverse Events in Cancer Patients

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood. Reducing the skin side effects of your cancer treatment may improve quality of life and allow participants to continue to receive their usual cancer treatment.

Conditions

• Solid Tumor
• Solid Carcinoma
• Solid Tumor, Adult
• Hematologic Malignancy

Interventions

Type	Name	Description
DRUG	Benralizumab	All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.

Timeline

• Start date: 2020-09-16
• Primary completion: 2024-07-19
• Completion: 2027-03-16
• First posted: 2020-09-17
• Last updated: 2026-04-16
• Results posted: 2025-04-29

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study